Endocr Rev (1998) 19(1):5579.10.1210/edrv.19.1.0324 172 LaronZ
Ozempic is focused on glucose control in diabetes, involving ongoing blood sugar testing and tight endocrinological oversight
Liraglutide: Impact on the metabolic composite of HbA1creduction AND weight loss The composite end point of HbA1creduction to below 7% and a greater than 5% of body weight loss was attained by 5 (16.7%) patients in the dulaglutide arm, while 20 (50%) patients on liraglutide arm reached this composite ( p = 0.75)
GLP-1 Case Study Name: Richard J., a 58-year-old male Medical History: Type 2 Diabetes Mellitus (diagnosed 7 years ago) Obesity (BMI 35 kg/m) Hypertension (well-controlled on an ACE inhibitor) Mild diabetic retinopathy Current Medications: Metformin 1000 mg twice daily, glimepiride 2 mg once daily, and lisinopril 20 mg once daily Clinical Presentation Richard presents a routine follow-up
Butterbur (petasites) : 75 mg twice a day
Researchers found that the tongue biopsies showed increased activity of genes associated with taste signaling transduction pathways, neural plasticity, and renewal of taste buds in the tongue, in those who took semaglutide
.jpg)
